Drug Discovery & Development |
EC approves Roche’s SC formulation of MabThera for common forms of non …
News-Medical.net Halozyme Therapeutics, Inc. (NASDAQ: HALO) announced today that the European Commission (EC) has approved Roche’s new subcutaneous (SC) formulation of MabThera® (rituximab) for the treatment of patients with follicular lymphoma and diffuse large … Europe OKs New Formula of Roche Cancer DrugDrug Discovery & Development Halozyme Platform Wins EC Approval for Roche’s MabThera SCGenetic Engineering News Halozyme: European Approval Of Roche’s MabThera SC For Non-Hodgkin …NASDAQ SYS-CON Media (press release) all 15 news articles » |
Patient Enrollment Completed in Multicenter European REMEDEE Registry of … – SYS-CON Media (press release)
Patient Enrollment Completed in Multicenter European REMEDEE Registry of …SYS-CON Media (press release)The COMBO Dual Therapy Stent is the first dual therapy stent to both accelerate endothelial coverage and control neo-intimal proliferation through …
Europa aprueba 'MabThera' (rituximab) subcutáneo para el tratamiento del … – infosalus.com
|
Europa aprueba ‘MabThera’ (rituximab) subcutáneo para el tratamiento del …
infosalus.com La Comisión Europea ha aprobado el uso de la formulación subcutánea (SC) de rituximab, comercializado por Roche con el nombre de ‘MabThera’, para el tratamiento de las clases de linfoma no Hodgkin (LNH) más frecuentes. Tras la aprobación de … |
Europa aprueba 'MabThera' (rituximab) subcutáneo para el tratamiento del … – Te Interesa
Redacción Médica |
Europa aprueba ‘MabThera’ (rituximab) subcutáneo para el tratamiento del …
Te Interesa La Comisión Europea ha aprobado el uso de la formulación subcutánea (SC) de rituximab, comercializado por Roche con el nombre de ‘MabThera’, para el tratamiento de las clases de linfoma no Hodgkin (LNH) más frecuentes. Tras la aprobación de … Europa da luz verde a MabThera, de Roche, por la vía subcutáneaRedacción Médica |
Treat sexual problems in lung cancer patients on priority say Experts – Daily News & Analysis
|
Treat sexual problems in lung cancer patients on priority say Experts
Daily News & Analysis Raising an issue that has been ignored for long in the case of lung cancer patients, experts have urged physicians to pay more attention on how such patients suffer difficulties with sexual expression and intimacy. “It is time that doctors and … |
Europa aprueba 'MabThera' (rituximab) subcutáneo para el tratamiento del … – TeleCinco.es
|
Europa aprueba ‘MabThera’ (rituximab) subcutáneo para el tratamiento del …
TeleCinco.es La Comisión Europea ha aprobado el uso de la formulación subcutánea (SC) de rituximab, comercializado por Roche con el nombre de ‘MabThera’, para el tratamiento de las clases de linfoma no Hodgkin (LNH) más frecuentes. Tras la aprobación de … |
Patient Enrollment Completed in Multicenter European REMEDEE Registry of … – PR Newswire (press release)
Patient Enrollment Completed in Multicenter European REMEDEE Registry of …PR Newswire (press release)… all-comers REMEDEE Registry (Multicenter, Prospective, Clinical Outcomes After Deployment of the Abluminal Sirolimus Coated Bio-Engineered Stent …
Adelaide woman who died of cancer is the inspiration for radical womb … – The Australian
Adelaide woman who died of cancer is the inspiration for radical womb …The AustralianAdelaide woman who died of cancer is the inspiration for radical womb transplant surgery. by: HEALTH REPORTER BRAD CROUCH; From: The Advertiser; March 28, 2014 11:52…
FDA panel rejects Novartis' heart failure hope serelaxin – PMLiVE
|
FDA panel rejects Novartis’ heart failure hope serelaxin
PMLiVE An FDA advisory committee voted unanimously against approval of Novartis’ acute heart failure (AHF) candidate serelaxin yesterday, although the company says it will stick with the project. As predicted, the panel agreed with the position taken by the … FDA Panel Rejects Novartis Drug for Heart FailureWall Street Journal FDA panel votes against Novartis drug for acute heart failureYahoo News UPDATE 2-FDA panel votes against Novartis drug for acute heart failureReuters Bloomberg all 37 news articles » |
Why sexual problems need to be treated in lung cancer patients – India.Com Health
India.Com Health |
Why sexual problems need to be treated in lung cancer patients
India.Com Health Heavy exposure to asbestos, radon, uranium, arsenic, genetic predisposition, and lung scarring from any prior illness can all cause lung cancer. Due to environmental pollution, lung cancer is increasing rapidly among Indian women in the 45 to 55 age group. Treat sexual problems in lung cancer patients on priority say ExpertsDaily News & Analysis Treat sexual problems in lung cancer patients on priority: ExpertsZee News |